艾多沙班与阿哌沙班在老年非瓣膜性心房颤动患者中的有效性和安全性比较:一项真实世界人群队列研究
该研究利用英国临床实践研究数据链,纳入2015至2021年间年龄≥80岁的新发非瓣膜性心房颤动患者,比较艾多沙班与阿哌沙班的有效性和安全性。结果显示,艾多沙班与阿哌沙班在血栓栓塞发生率上相似,但艾多沙班的大出血风险更高。
要点
- 在≥80岁非瓣膜性心房颤动患者中,艾多沙班与阿哌沙班的血栓栓塞发生率相似。
- 艾多沙班的大出血发生率高于阿哌沙班。
- 艾多沙班的复合结局风险高于阿哌沙班,全因死亡率相似。
核心结论
- 在非常高龄的非瓣膜性心房颤动患者中,艾多沙班预防血栓栓塞的效果与阿哌沙班相似,但与大出血风险升高相关。
研究设计与样本
- 基于英国临床实践研究数据链的真实世界人群队列研究,纳入2015至2021年间年龄≥80岁的新发非瓣膜性心房颤动患者,艾多沙班组7251例,阿哌沙班组39991例,采用倾向评分精细分层和加权调整混杂,使用加权Cox比例风险模型估计风险比。
主要发现
- 艾多沙班组与阿哌沙班组的血栓栓塞调整发生率分别为20.38/1000人年与19.22/1000人年,调整HR为1.06(95%CI 0.89-1.26)。
- 艾多沙班组与阿哌沙班组的大出血调整发生率分别为45.57/1000人年与31.21/1000人年,调整HR为1.42(95%CI 1.26-1.61)。
- 艾多沙班组复合结局风险较阿哌沙班组高21%,调整HR为1.21(95%CI 1.07-1.38)。
- 艾多沙班组与阿哌沙班组的全因死亡率相似,调整HR为1.04(95%CI 0.96-1.12)。
临床怎么用
- 这些发现可能通过为临床医生在选择抗凝药物时提供信息,改善这一脆弱人群的非瓣膜性心房颤动管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The very elderly (≥80 years) are at high risk of nonvalvular atrial fibrillation and thromboembolism. Given its recent approval, the comparative effectiveness and safety of edoxaban in this population, relative to the commonly used apixaban, remain unknown. METHODS: Using the United Kingdom Clinical Practice Research Datalink, we identified a cohort of patients aged ≥80 with incident nonvalvular atrial fibrillation and newly treated with edoxaban or apixaban between 2015 and 2021. Cohort entry was defined as the first prescription for one of the 2 drugs. We used propensity score fine stratification and weighting for confounding adjustment. A weighted Cox proportional hazards model was used to estimate the hazard ratios (HR) with 95% CI of ischemic stroke/transient ischemic attack/systemic embolism (primary effectiveness outcome) and of major bleeding (primary safety outcome) associated with edoxaban compared with apixaban. We also assessed the risk of all-cause mortality and a composite outcome of ischemic stroke/transient ischemic attack, systemic embolism, gastrointestinal bleeding, and intracranial hemorrhage as secondary outcomes. RESULTS: The cohort included 7251 new-users of edoxaban and 39 991 of apixaban. Edoxaban and apixaban had similar incidence rates of thromboembolism (adjusted rates, 20.38 versus 19.22 per 1000 person-years; adjusted HR, 1.06 [95% CI, 0.89-1.26]), although the rates of major bleeding were higher with edoxaban (adjusted rates, 45.57 versus 31.21 per 1000 person-years; adjusted HR, 1.42 [95% CI, 1.26-1.61]). The risk of the composite outcome was 21% higher with edoxaban (adjusted HR, 1.21 [95% CI, 1.07-1.38]). All-cause mortality was similar between edoxaban and apixaban (adjusted HR, 1.04 [95% CI, 0.96-1.12]). CONCLUSIONS: In very elderly patients with nonvalvular atrial fibrillation, edoxaban resulted in similar thromboembolism prevention as apixaban, although it was associated with a higher risk of major bleeding. These findings may improve the management of nonvalvular atrial fibrillation by informing physicians on the choice of anticoagulant for this vulnerable population.
引用
- Chiv R, Beradid S, Suissa S, et al. Effectiveness and Safety of Edoxaban Compared With Apixaban in Elderly Patients With Nonvalvular Atrial Fibrillation: A Real-World Population-Based Cohort Study. Stroke. 2024. PMID: 38511316. doi:10.1161/STROKEAHA.123.045098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。